Steven N. Fishbane

Steven N. Fishbane's AcademicInfluence.com Rankings

Steven N. Fishbane

Philosophy

#8554

World Rank

#11961

Historical Rank

Logic

#5583

World Rank

#6992

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Steven N. Fishbane's Degrees

Doctorate Medicine Albert Einstein College of Medicine
PhD Biochemistry Albert Einstein College of Medicine

Why Is Steven N. Fishbane Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Steven N. Fishbane's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Acute kidney injury in patients hospitalized with COVID-19 (2020) (1003)
Acute kidney injury in patients hospitalized with COVID-19 (2020) (1003)
KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease (2012) (793)
Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease (2012) (757)
Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. (2013) (564)
A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. (2002) (306)
Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. (2005) (287)
The safety of intravenous iron dextran in hemodialysis patients. (1996) (248)
Regulation of renal urate excretion: a critical review. (1998) (233)
Self-assessed physical and mental function of haemodialysis patients. (2001) (224)
Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. (1997) (221)
Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management (2014) (218)
Hemoglobin variability and mortality in ESRD. (2007) (208)
Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. (2002) (198)
Outcomes of patients with end-stage kidney disease hospitalized with COVID-19 (2020) (195)
Outcomes of patients with end-stage kidney disease hospitalized with COVID-19 (2020) (195)
Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. (2008) (194)
Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. (2009) (192)
N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. (2004) (185)
A randomized trial of iron deficiency testing strategies in hemodialysis patients. (2001) (179)
Iron management in end-stage renal disease. (1997) (173)
Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. (2008) (173)
Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. (1995) (172)
The evaluation of iron status in hemodialysis patients. (1996) (170)
Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. (2018) (164)
Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. (2009) (158)
Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury (2020) (156)
Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury (2020) (156)
Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA) (2007) (152)
Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. (2007) (142)
Hemoglobin variability in epoetin-treated hemodialysis patients. (2003) (141)
Hyponatremia in Community-Acquired Pneumonia (2007) (139)
A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. (2015) (131)
Cerebral Salt-Wasting Syndrome: Does It Exist? (1999) (130)
Safety in iron management. (2003) (126)
Preservation of residual kidney function in hemodialysis patients: reviving an old concept. (2016) (124)
Role of volume overload in dialysis-refractory hypertension. (1996) (124)
N-acetylcysteine in the prevention of contrast-induced nephropathy. (2008) (116)
KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease (2018) (114)
Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management (2015) (101)
Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. (2019) (100)
Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. (2003) (99)
Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. (2013) (98)
Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. (2017) (96)
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients (2017) (95)
Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. (1996) (91)
Considerations and challenges in defining optimal iron utilization in hemodialysis. (2015) (86)
Review of issues relating to iron and infection. (1999) (84)
Peginesatide in patients with anemia undergoing hemodialysis. (2013) (83)
History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. (2008) (78)
Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib. (2015) (75)
Occult infection of old nonfunctioning arteriovenous grafts: a novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. (2002) (73)
Iron toxicity: relevance for dialysis patients. (2014) (72)
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. (2019) (70)
Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. (2021) (68)
Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix. (1997) (67)
More on renal salt wasting without cerebral disease: response to saline infusion. (2009) (63)
Risk for Acute Renal Failure in Patients Hospitalized for Decompensated Congestive Heart Failure (2007) (62)
The beliefs and expectations of patients and caregivers about home haemodialysis: an interview study (2013) (61)
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. (2021) (60)
Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. (2003) (60)
Renal salt wasting without cerebral disease: diagnostic value of urate determinations in hyponatremia. (2007) (60)
Self-Assessed Quality of Life in Peritoneal Dialysis Patients (2001) (60)
Increased bone fractures among elderly United States hemodialysis patients. (2014) (59)
Serum Ferritin in Chronic Kidney Disease: Reconsidering the Upper Limit for Iron Treatment (2004) (57)
Ankle-arm blood pressure index as a marker for atherosclerotic vascular diseases in hemodialysis patients. (1995) (57)
The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. (1995) (56)
Update on membranoproliferative GN. (2014) (55)
The impact of standardized order sets and intensive clinical case management on outcomes in community-acquired pneumonia. (2007) (55)
Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century (2016) (55)
Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review (2016) (54)
Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells. (2004) (53)
Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients (2015) (53)
Clinical Management of Hyperkalemia. (2020) (49)
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. (2008) (49)
Reducing hospital readmissions in patients with end-stage kidney disease. (2015) (48)
Bone histology in patients with nephrotic syndrome and normal renal function. (1999) (44)
The new FDA label for erythropoietin treatment: how does it affect hemoglobin target? (2007) (43)
Iron management in nondialysis-dependent CKD. (2007) (43)
Augmented Nurse Care Management in CKD Stages 4 to 5: A Randomized Trial. (2017) (39)
Prostaglandin D2 synthase induces apoptosis in PC12 neuronal cells (2001) (39)
Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. (2007) (39)
The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. (1995) (38)
Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients (2020) (37)
Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease. (2019) (37)
Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment. (2012) (37)
Cardiovascular risk evaluation before kidney transplantation. (2005) (36)
Acute kidney injury in pediatric patients hospitalized with acute COVID-19 and multisystem inflammatory syndrome in children associated with COVID-19 (2021) (36)
Hypervitaminosis A in two hemodialysis patients. (1995) (35)
Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. (2015) (35)
Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. (1997) (35)
Challenges and opportunities in late-stage chronic kidney disease* (2014) (34)
Prevalence and outcomes of hyponatremia and hypernatremia in patients hospitalized with COVID-19 (2021) (34)
Anemia and cardiovascular risk in the patient with kidney disease. (2008) (34)
Prevalence and outcomes of hyponatremia and hypernatremia in patients hospitalized with COVID-19 (2021) (34)
Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection (2022) (33)
Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses (2018) (33)
COVID-19 in Hospitalized Patients on Chronic Peritoneal Dialysis: A Case Series (2020) (32)
Anemia management in chronic kidney disease. (2010) (32)
Editorials: Recombinant Human Erythropoietin: Has Treatment Reached its Full Potential? (2006) (32)
Managing anemia in dialysis patients: hemoglobin cycling and overshoot. (2008) (31)
Longitudinal predictors of uremic pruritus. (2013) (31)
Increasing Hip Fractures in Patients Receiving Hemodialysis and Peritoneal Dialysis (2014) (31)
Posttransplant anemia: the role of sirolimus. (2009) (30)
Pharmacokinetic and Pharmacodynamic Properties of Methoxy Polyethylene Glycol‐Epoetin Beta Are Unaffected by the Site of Subcutaneous Administration 1 (2007) (30)
Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System. (2016) (29)
A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. (2010) (29)
Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. (2001) (29)
Clinician beliefs and attitudes about home haemodialysis: a multinational interview study (2012) (28)
Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study (2020) (28)
Proximal calciphylaxis in four insulin-requiring diabetic hemodialysis patients. (1996) (28)
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. (2020) (27)
Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis (2020) (27)
Editorial: The Optimal Hemoglobin in Dialysis Patients— A Critical Review (2007) (27)
Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer. (2014) (26)
Beneficial effects of iron therapy in renal failure patients on hemodialysis. (1999) (26)
Upper Limit of Serum Ferritin: Misinterpretation of the 2006 KDOQI Anemia Guidelines (2008) (25)
Iron supplementation in renal anemia. (2006) (25)
Bone Parameters and Risk of Hip and Femur Fractures in Patients on Hemodialysis. (2016) (24)
Introduction of Biosimilar Therapeutics Into Nephrology Practice in the United States: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. (2016) (22)
Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease (2017) (22)
The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial. (2013) (21)
Prostaglandin D2 synthase induces apoptosis in pig kidney LLC-PK1 cells (2001) (21)
Hepatic iron in hemodialysis patients. (2004) (19)
Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19 (2020) (19)
Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. (2007) (19)
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study (2022) (19)
Recipient Criteria Predictive of Graft Failure in Kidney Transplantation (2015) (18)
The emerging role of biosimilar epoetins in nephrology in the United States. (2015) (18)
Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective. (2009) (17)
Changes to the end-stage renal disease quality incentive program. (2012) (17)
Opportunities for Increasing the Rate of Preemptive Kidney Transplantation. (2018) (17)
Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial. (2019) (17)
Prostaglandin D(2) synthase induces apoptosis in pig kidney LLC-PK1 cells. (2001) (17)
Iron treatment: impact of safety issues. (1998) (17)
Quality Measurement in Wonderland: The Curious Case of a Dialysis Readmissions Measure. (2016) (16)
Treatment Target in Polycythemia Vera (2013) (16)
Weight trends in United States living kidney donors: Analysis of the UNOS database. (2015) (16)
Pheochromocytoma multisystem crisis in a patient with multiple endocrine neoplasia type IIB and pyelonephritis. (2002) (16)
The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients (2005) (15)
Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. (2012) (15)
Intravenous iron exposure and outcomes in patients on hemodialysis. (2014) (15)
Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis. (2016) (15)
Potentially Avoidable Readmissions in United States Hemodialysis Patients (2017) (15)
Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease. (2018) (14)
Epidemiology and Challenges to the Management of Advanced CKD. (2016) (14)
Clofarabine-induced kidney toxicity (2014) (13)
Removal of Foley Catheters in Live Donor Kidney Transplant Recipients on Postoperative Day 1 Does Not Increase the Incidence of Urine Leaks (2013) (13)
Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate (2017) (12)
‘WhatsApp®’ening in nephrology training (2019) (12)
The effect of hemodialysis ultrafiltration on changes in whole blood viscosity (2012) (12)
Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure. (2018) (12)
Paraneoplastic syndromes of the kidney. (1997) (12)
Contribution of prostaglandin D2 synthase to progression of renal failure and dialysis dementia. (2002) (11)
Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials (2020) (11)
Diagnosis of Iron Deficiency in End‐Stage Renal Disease (1999) (10)
Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis (2017) (10)
Drug Insight: safety of intravenous iron supplementation with sodium ferric gluconate complex (2006) (10)
Anemia in chronic kidney disease: status of new therapies. (2009) (10)
Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKD (2019) (10)
Porphyria cutanea tarda in a patient on chronic ambulatory peritoneal dialysis. (1996) (10)
The Value of Intravenous Iron: Beyond the Cave of Speculation. (2020) (9)
The effect of improved dialytic efficiency on measures of appetite in peritoneal dialysis patients (1996) (9)
Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation. (2021) (9)
Is there material hazard to treatment with intravenous iron? (1999) (9)
How we treat Renal Anemia. (2020) (9)
Methods and rationale of the DISCOVER CKD global observational study (2021) (9)
Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex. (2017) (8)
The role of erythropoiesis-stimulating agents in the treatment of anemia. (2010) (8)
Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure. (2010) (8)
Editorial Focus: Dialysis Quality and Outcomes: Quality Outcomes and Obstacles to Their Achievement in End‐Stage Renal Disease (2002) (8)
The effect of KT/V(urea) on nitrogen appearance and appetite in peritoneal dialysis. (1995) (8)
Medication discrepancies in late-stage chronic kidney disease (2017) (8)
What Is Needed to Achieve a Hemoglobin of 11.0–13.0 g/dl in End-Stage Renal Disease (2006) (7)
Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease. (2016) (7)
A multicenter study of the safety of intravenous iron dextran (IVFe) in hemodialysis patients (1996) (7)
Meeting the 2012 QIP (Quality Incentive Program) clinical measures: strategies for dialysis centers. (2012) (7)
Anemia in Non-Dialysis-Dependent CKD: To Treat or Not to Treat? (2019) (7)
A physician's perseverance uncovers problems in a key nephrology study. (2012) (6)
Research directions: new clinical frontiers. (2000) (6)
Novel iron-based phosphate binders in patients with chronic kidney disease (2015) (6)
Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection (2020) (6)
Outcomes following Kidney transplantation in IgA nephropathy: a UNOS/OPTN analysis (2015) (6)
Shortened Length of Stay Improves Financial Outcomes in Living Donor Kidney Transplantation (2013) (6)
Iron deficiency in non-dialysis chronic kidney disease. (2009) (6)
Subgroup analyses in nephrology clinical trials. (2012) (6)
Partial characterization of apoptotic factor in Alzheimer plasma. (1999) (6)
NARRATIVE REVIEW Iron Management in Nondialysis-Dependent CKD (2007) (6)
Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa. (2013) (6)
The Effect of Ktn on Nitrogen Appearance and Appetite Urea in Peritoneal Dialysis (1995) (5)
Is there an established hemoglobin target range for patients undergoing chronic dialysis? (2018) (5)
Safety issues with iron sucrose. (2003) (5)
Anemia treatment in chronic renal insufficiency. (2002) (5)
Practice patterns in transitioning patients from chronic kidney disease to dialysis: a survey of United States nephrologists (2018) (5)
Improvement of Hemodialysis Catheter Function with Tenecteplase: A Phase III, Open-Label Study: TROPICS 4 (2010) (5)
Tenecteplase for the improvement of blood flow rate in dysfunctional hemodialysis catheters. (2010) (5)
Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program (2022) (5)
The New Label for Erythropoiesis Stimulating Agents: The FDA’S Sentence (2012) (5)
Hemoglobin response to ferric citrate in patients with nondialysis‐dependent chronic kidney disease and iron deficiency anemia (2018) (5)
How Can Erythropoeitin‐Stimulating Agent Use be Reduced in Chronic Dialysis Patients? (2013) (4)
Phospholipase A2 Receptor Antibody-Positive Pregnancy: A Case Report. (2020) (4)
Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease (2019) (4)
Quality of reporting of randomization methodology in nephrology trials. (2012) (4)
59: Efficacy of C.E.R.A., a Continuous Erythropoietin Receptor Activator, in Treatment of Renal Anemia: Overview of 6 Global Phase 3 Trials (2007) (4)
Nephrology Crossword: Onco-nephrology--chemotherapy agents and nephrotoxicity. (2013) (4)
Treating desmopressin-induced hyponatremia: a case using hypertonic saline. (2013) (4)
Review: recombinant human erythropoietin decreases the need for blood transfusions and may delay dialysis in chronic renal failure. (2002) (3)
Abstract 16610: Efficacy and Safety of Sodium Zirconium Cyclosilicate to Treat Hyperkalemia Among Patients Taking Renin-Angiotensin-Aldosterone System Inhibitors in a 12-Month, Open-Label, Phase 3 Study: A Post Hoc Subgroup Analysis (2017) (3)
Intravenous infusion of total dose iron in peritoneal dialysis patients: a critical appraisal. (1998) (3)
Improving outcomes in late-stage kidney disease: the healthy transitions program. (2014) (3)
Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease. (2019) (3)
FP071SAFETY AND EFFICACY OF SODIUM ZIRCONIUM CYCLOSILICATE FOR LONG-TERM TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: RESULTS FROM AN OPEN-LABEL, PHASE 3 STUDY (2018) (3)
Glomerular diseases: entering a new era. (2014) (3)
Consensus-Based Recommendations for the Management of Hyperkalemia in the Hemodialysis Setting. (2021) (3)
Cyclical cardiorenal syndrome in late-stage kidney disease . (2018) (3)
Phosphate Absorption and Hyperphosphatemia Management in Kidney Disease: A Physiology-Based Review (2021) (3)
SP421SODIUM ZIRCONIUM CYCLOSILICATE FOR HYPERKALAEMIA IN PATIENTS WITH DIABETES MELLITUS: RETROSPECTIVE ANALYSIS OF A 12 MONTH OPEN LABEL, PHASE 3 STUDY (2018) (3)
Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies (2019) (2)
Anemia management: a historical perspective (2021) (2)
Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Prospective Observational Study. (2020) (2)
What are the Considerations in Balancing Benefits and Risks in Iron Treatment? (2017) (2)
Meeting New Challenges in the Management of Anemia of Chronic Kidney Disease Through Collaborative Care with Pharmacists (2009) (2)
EPO adjuvant treatments: a need for more evidence. (2006) (2)
How Can Erythropoeitin‐Stimulating Agent Use be Reduced in Chronic Dialysis Patients? (2013) (2)
A Consensus on Current Issues and Controversies in Iron Management of Patients with Chronic Renal Failure (1999) (2)
Forty‐eight hour kidney transplant admissions (2013) (2)
Home Dialysis in the Time of COVID-19: Reflections on Rapidly Changing Policies (2020) (2)
ANEMIA , CHRONIC KIDNEY DISEASE , AND CARDIOVASCULAR DISEASE : THE CLINICAL TRIALS — (2)
The surge in nephrology consultations and inpatient dialysis services during the COVID-19 pandemic. (2020) (2)
Hypothesis: an erythropoietin honeymoon phase exists. (2010) (2)
Living Well With Kidney Disease and Effective Symptom Management: Consensus Conference Proceedings (2022) (2)
More Frequent Hemoglobin ( Hb ) Measurements and Erythropoiesis-Stimulating Agent ( ESA ) Titrations are Not Associated With Increased Time in Target Hb Range (2012) (1)
Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD (2022) (1)
Chapter 7 – Anemia in Chronic Kidney Disease (2005) (1)
Authors' Reply. (2021) (1)
58: C.E.R.A. Once Monthly Maintains Stable HB Levels in Patients with CKD on Dialysis with and without Congestive Heart Failure (CHF) (2007) (1)
Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease (2022) (1)
Should Target Hemoglobin Levels in Dialysis Patients be Lowered to 9–10 g/dl? (2014) (1)
POS-328 THE BURDEN OF HYPERKALEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT (2021) (1)
Iron management in ESRD and the role of the nephrology nurse. (1997) (1)
Choice of erythropoiesis stimulating agent in ESRD. (2013) (1)
The Relationship Between Medication Discrepancies and Hospitalization Risk Among Patients With Advanced CKD (2019) (1)
Treating chronic renal insufficiency : The nephrologist vs. the internist : (A commentary) (2000) (1)
Administrative Leadership: Nephrologists in Non-nephrology Leadership Roles. (2018) (1)
39: Assessing the Use of the Calcimimetic Cinacalcet with Low Dose Vitamin D Versus Escalating Doses of Vitamin D Alone in the Treatment of Secondary Hyperparathyroidism (HPT)—The Achieve Study (2007) (1)
Abstract No. 253: A phase III, open-label study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 4 (2010) (1)
A Woman with ESRD with Increasing Need for Erythropoietin to Maintain Hemoglobin. (2017) (1)
Hypertension in Dialysis Patients (2000) (1)
Anaemia: FIND-CKD: intravenous iron in predialysis CKD (2014) (1)
Acute kidney injury in patients hospitalized withCOVID-19. (2020) (1)
PowerPoint Slides for: Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients (2017) (1)
Stabilizing hemoglobin levels: what's new in IV iron and anemia management? (2008) (1)
POS-329 TREATMENT PATTERNS IN CHRONIC KIDNEY DISEASE PATIENTS WITH HYPERKALEMIA: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT (2021) (0)
MO424: Relationship Between Itch Intensity and Patient-Reported Disease Improvement in Patients With Chronic Kidney Disease-Associated Pruritus Treated With Difelikefalin (2022) (0)
IN-DEPTH REVIEW Iron Management in End-Stage Renal Disease (1997) (0)
Hypoxia-inducible factor stabilizers: 27 228 patients studied, yet a role still undefined (2023) (0)
Peginesatide for anemia in chronic kidney disease. (2013) (0)
Identification of an apoptotic factor(AF) found in Alzheimer's disease (AD) plasma and isolated from their urine (2000) (0)
SAT-128 Evaluating the Accuracy of Glycemic Markers and Risk of Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease by Continuous Glucose Monitoring (2019) (0)
A New View of Iron Management in Heart Failure: What Nephrologists Need to Know. (2021) (0)
Ferric pyrophosphate citrate for parenteral administration of maintenance iron: structure, mechanism of action, clinical efficacy and safety (2022) (0)
Introduction to unresolved issues in the care of dialysis patients (2018) (0)
Course of Hyperkalemia in Patients on Hemodialysis (2022) (0)
CKD PATHOPHYSIOLOGY AND CLINICAL STUDIES (2014) (0)
Partial characterization of apoptotic factor in Alzheimer plasma. (1999) (0)
Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE (2022) (0)
On Peginesatide and Anemia Treatment in CKD (2013) (0)
Avoidable Readmissions in United States Hemodialysis Patients (2018) (0)
FP684POTENTIALLY PREVENTABLE READMISSIONS IN CHRONIC HEMODIALYSIS PATIENTS (2015) (0)
Roxadustat for Anemia in Patients with Chronic Kidney Disease. (2020) (0)
Haplo-Storm induced acute kidney injury (2022) (0)
POS-305 HOSPITALIZATIONS AND LENGTH OF STAY IN PATIENTS WITH CKD WITH AND WITHOUT HYPERKALEMIA: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT (2022) (0)
Erratum to: Sodium Zirconium Cyclosilicate Increases Serum Bicarbonate Concentrations Among Patients with Hyperkalaemia: Exploratory Analyses from Three Randomized, Multi-Dose, Placebo-Controlled Trials (2020) (0)
Iron Deficiency in Dialysis Patients: Current Views on Diagnosis and Management (1999) (0)
Induction of apoptosis in neuronal cells by a plasma factor found in Alzheimer's disease (AD) (2000) (0)
Chapter 50 – Anemia in Patients With End-Stage Kidney Disease (2017) (0)
POS-258 CARDIOVASCULAR OUTCOMES AND EXPLORATORY ANALYSES BY ACHIEVED HB LEVELS IN THE POOLED PHASE 3 ROXADUSTAT STUDIES OF NON-DIALYSIS-DEPENDENT PATIENTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE (2021) (0)
Treatment with Erythropoiesis Stimulating Agents in Patients with Chronic Kidney Disease Complicated by Cancer (2017) (0)
Serum potassium laboratory reference ranges influence provider treatment behaviors for hyperkalemia. (2020) (0)
P0242SUBGROUP EFFICACY ANALYSIS OF SODIUM ZIRCONIUM CYCLOSILICATE (SZC) IN HYPERKALAEMIC HAEMODIALYSIS PATIENTS IN THE DIALIZE STUDY (2020) (0)
P0189SODIUM ZIRCONIUM CYCLOSILICATE CORRECTS HYPERKALAEMIA WITHIN 72 HOURS AMONG OUTPATIENTS WITH SEVERE HYPERKALAEMIA (BASELINE SERUM POTASSIUM ≥6 MMOL/L) REGARDLESS OF RENAL FUNCTION LEVEL OR RAASI USE: POST HOC SUBGROUP ANALYSIS OF A PHASE 3 TRIAL (2020) (0)
Dialysis: ESA responsiveness and outcomes in patients on hemodialysis (2012) (0)
POS-284 CARDIOVASCULAR OUTCOMES AND EXPLORATORY ANALYSES BY ACHIEVED HB LEVELS IN POOLED PHASE 3 TRIALS OF ROXADUSTAT IN DIALYSIS-DEPENDENT PATIENTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE (2021) (0)
FC 077LONG-TERM SAFETY OF TENAPANOR FOR THE CONTROL OF SERUM PHOSPHORUS IN PATIENTS WITH CKD ON DIALYSIS (2021) (0)
Hypokalemia Events With Sodium Zirconium Cyclosilicate and Placebo in Hemodialysis Patients (2022) (0)
Resource Use in Adult Dual Kidney Transplantation(DKT): Analysis of the United Network of Organ Sharing(UNOS) Database.: Abstract# C1861 (2014) (0)
Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis. (2023) (0)
P0198SODIUM ZIRCONIUM CYCLOSILICATE INCREASES SERUM BICARBONATE CONCENTRATIONS AMONG PATIENTS WITH HYPERKALAEMIA: RESULTS FROM THREE RANDOMIZED, MULTI-DOSE, PLACEBO CONTROLLED TRIALS (2020) (0)
Retraction notice to “Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.” Kidney Int Rep. 2021;6:613–623 (2022) (0)
Introduction: Iron Management in Chronic Kidney Disease. (2016) (0)
Difelikefalin in Hemodialysis Patients with Pruritus. Reply. (2020) (0)
P0220EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE (SZC) IN HAEMODIALYSIS PATIENTS WITH SEVERE HYPERKALAEMIA IN THE DIALIZE STUDY (2020) (0)
170 - Safety and Efficacy of Ferric Citrate in Patients with Nondialysis-Dependent Chronic Kidney Disease and Iron Deficiency Anemia: Post Hoc Analysis in Patients with or Without Heart Failure (2017) (0)
AN ANALYSIS OF AN EMERGENCY DEPARTMENT TRIAGE PROGRAM FOR RAPID IDENTIFICATION OF COMMUNITY-ACQUIRED PNEUMONIA (2008) (0)
MO538 THE SHORT-TERM IMPACT OF HIGH DOSE INTRAVENOUS IRON USE ON RENAL FUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND IRON DEFICIENCY WITHOUT ANAEMIA - A POST-HOC ANALYSIS OF A MULTICENTRE RANDOMIZED CONTROLLED TRIAL* (2021) (0)
193: Safety and Tolerability of C.E.R.A. (A Continuous Erythropoietin Receptor Activator) in Patients With Chronic Kidney Disease: Pooled Data From Ten Phase II-III Trials (2007) (0)
Pruritus in chronic kidney disease (2022) (0)
The authors reply. (2020) (0)
POS-503 EVALUATING CHRONIC KIDNEY DISEASE PROGRESSION: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT (2021) (0)
Improving Detection and Management of Anemia in CKD. (2022) (0)
Announcement / Book Reviews (1999) (0)
MO539HEMATOLOGIC EFFICACY OF VADADUSTAT FOR ANEMIA IN PATIENTS WITH KIDNEY FAILURE ON DIALYSIS (2021) (0)
Intravenous iron treatment: a comparison of available drugs (2002) (0)
306 Risk of Acute Kidney Injury in COVID-19 is Increased in African Americans With APOL1 High-Risk Genotype (2021) (0)
POS-283 HEMOGLOBIN (HB) CORRECTION WITH ROXADUSTAT IS ASSOCIATED WITH IMPROVED IRON HOMEOSTASIS IN PATIENTS WITH NON-DIALYSIS-DEPENDENT (NDD) AND DIALYSIS-DEPENDENT (DD) CHRONIC KIDNEY DISEASE (CKD) (2021) (0)
Efficacy of Treatments Targeting the Calcium- Sensing Receptor, Ca R, and Vitamin D Receptor, V D R, in Controlling Parathyroid Hormone, P T H, in Hemodialysis Patients (2008) (0)
Use of TIMP-2 and IGFBP-7 for prediction of postoperative acute kidney injury after cardiac surgery. (2022) (0)
WCN23-0671 BASELINE CHARACTERISTICS OF PATIENTS ENROLLED IN THE DISCOVER CKD PROSPECTIVE STUDY (2023) (0)
Pruritus in chronic kidney disease. (2022) (0)
Effectiveness of Sodium Zirconium Cyclosilicate in Hemodialysis Patients With Severe Hyperkalemia (2021) (0)
Unmet Medical Needs in Chronic-Kidney-Disease-Associated Pruritus (2021) (0)
Refractory anemia in a patient with allergy to intravenous iron drugs. (2006) (0)
Anemia in CKD in Primary Care: Executive Summary. (2022) (0)
Dual Adult Kidney Transplants (DKT):Analysis of the United Network of Organ Sharing (UNOS) Database 2006-2011.: Abstract# 2873 (2014) (0)
MO214EVALUATION OF THE EFFECT OF A POTASSIUM BINDER ON ARRHYTHMIA-RELATED CARDIOVASCULAR OUTCOMES IN PATIENTS ON CHRONIC HAEMODIALYSIS WITH RECURRENT HYPERKALAEMIA: DESIGN AND RATIONALE FOR THE SODIUM ZIRCONIUM CYCLOSILICATE DIALIZE-OUTCOMES STUDY (2021) (0)
Enalapril delayed end-stage renal failure in patients with chronic renal failure and hypertension (1995) (0)
POS-282 ROXADUSTAT TREATMENT RESULTS IN CONSISTENT IMPROVEMENTS IN HEMOGLOBIN (HB) VERSUS PLACEBO: AN ANALYSIS OF THREE MULTINATIONAL RCTS IN PATIENTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Steven N. Fishbane?

Steven N. Fishbane is affiliated with the following schools:

Hofstra University
Winthrop University